Categories AlphaGraphs, Analysis, Retail
Skechers earnings preview: Wall St expects 13% jump in Q4 revenue
Shoemaker Skechers (SKX) will report fourth-quarter earnings results after the regular trading hours on Thursday, February 7. The company is expected to report a 13% increase in revenues to $1.1 billion.
The top line is expected to be boosted by strong demand for its products outside the domestic markets, primarily in China and Europe. Skechers has inked numerous partnerships and JVs to effectively deliver its products to key global markets.
The company’s digital platform has also been slowly picking up and is expected to lift overall sales. However, only a part of this sales hike would be transferred to the bottom line as higher taxes and currency headwinds weigh on the results.
While the company management has given Q4 EPS guidance in the range of $0.20–0.25, analysts on an average expect earnings to be 23 cents per share.
During the earnings conference call, look out for management comments on the firm’s cost management strategies, besides its plan of action to boost international growth. Investors would also be interested to know what the company plans to do with its domestic wholesale business, which has been showing signs of weakness.
During the last reported quarter, revenue from the wholesale business fell 3% year-over-year.
SKX stock has a 12-month average price target of $27.67, which is at a modest 1.6% upside from the last close. Therefore, even strong fourth-quarter results might keep a stock rally under check.
In Q3
In the last reported quarter, earnings declined modestly, but to a lesser extent compared to analysts’ forecast. The stock gained about 7% during the extended trading hours as the market responded positively to the results and upbeat outlook.
Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference, and much more!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on